Riyadh Biotechnology Summit 2026 integrates data computing with drug discovery and targets 65 international agreements

Saudi capital is preparing to host the fourth edition of the Riyadh Global Summit on Medical Biotechnology 2026 from 14 to 16 September 2026, at the Sofitel Riyadh Hotel and Conference Center under the patronage of Crown Prince and Prime Minister Mohammed bin Salman. This year's summit will be held under the theme “Building Foundations of Excellence in Biotechnology”, with participation of the Saudi Data and AI Authority (SDAIA), the Ministry of Investment and the “Invest in Saudi Arabia” platform as main strategic partners, in a step that cements the meeting of data science and AI with advanced bio and pharmaceutical research.

The summit focuses on precise technological and scientific tracks includinggenomics, gene and cell therapy, biomanufacturing, immunology, and AI-enabled drug discoveryIt is expected to attract more than 15,000 visitors, with over 100 local and international speakers, 200 healthcare and biotechnology brands, more than 80 exhibiting entities representing the public and private sectors, and official delegations from over 70 countries.

These moves are part of the goals of Saudi Arabia’s National Biotechnology Strategy, which seeks to contribute $34.6 billion to the non-oil gross domestic product by 2040. In its three previous editions, the summit has seen 59 agreements signed with prominent global partners such as Pfizer, AstraZeneca and Novo Nordisk, while the 2024 edition alone secured announced deals worth more than $100 million, and the 2026 edition targets signing more than 65 agreements and memoranda of understanding over its three days.

The summit hosts a select group of international academic and industry leaders, including Professor Keith Flaherty of Massachusetts General Hospital and Harvard Medical School, Mitsuo Ouchi, President of Hiroshima University, Dr. Steve Yang, Co-Chief Executive Officer of Voxy Aptik, Professor Matthew Portius of Stanford University, Professor Jin-Su Kim of the Korea Advanced Institute of Science and Technology (KAIST), Dr. Alex Chalick, Director of the Institute of Medical Engineering and Science at the Massachusetts Institute of Technology (MIT), Dr. Hyun-Young Park of the College of Medicine at Ulsan University, and Dr. Arturo Luiza-Bonilla, co-founder and Chief Medical Officer for AI at Massive Bio.

Data and AI infrastructure joins as a strategic partner at the summitIt reshapes the region’s health-care work and innovation requirements; the focus is no longer limited to digital services and medical record management, but has shifted to employing machine-learning algorithms in drug-molecule discovery pipelines and cell engineering. This shift imposes on technical teams and health institutions in the Gulf, Egypt and the Arab Levant the need to build specialized expertise in bio-computing and complex clinical data management, and to open pathways for local joint biomanufacturing contracts instead of relying solely on imported ready-made therapies.

Registration has officially opened to delegations, exhibitors and industry partners, marking the start of direct coordination for deal-making and expanding research alliances, at a time when strategic capital is accelerating toward bio-infrastructures with long-term economic returns.